[Summary] 细胞免疫治疗
药明巨诺(港交所代码:2126)是一家独立的、专注于开发、生产及商业化细胞免疫治疗产品的创新型生物科技公司。药明巨诺已打造了细胞免疫疗法的技术与产品开发平台,以及涵盖血液及实体肿瘤、极具潜力的产品管线,以期为中国乃至全球患者带来治愈的希望,并促进中国细胞免疫治疗产业的健康规范发展。
JW Therapeutics (HKEx: 2126) is an independent, innovative biotechnology company focusing on developing, manufacturing commercializing cell immunotherapy products. Founded in 2016, JW Therapeutics is committed to becoming an innovation leader in cell immunotherapy. The company has built a world- platform ftechnology product development in cell immunotherapy, as well as a promising product pipeline covering both hematologic mancies solid tumors, to bring the hope of a cure fChinese global patients, to lead the healthy standardized development of China’s cell immunotherapy industry.
What does 上海药明巨诺生物科技有限公司 require? Who is 药明巨诺 hiring? 药明巨诺招聘类别销售类占比最多占61.7%,其次是经营管理类占41.7%。药明巨诺什么学历能进?本科占比最多占73.3%,其次是硕士占16.7%。药明巨诺学历要求高吗?硕士占16.7%。工作经验药明巨诺有什么要求?1-3年占比最多占56.7%,其次是5-10年占15%。药明巨诺工作地区在哪?上海占比最多占41.7%,其次是苏州占11.7%。 Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows